DCC/netrin-1 regulates cell death in oligodendrocytes after brain injury

Madelen M Díaz1, Yanina Tsenkina1, Dena Arizanovska1

  • 1The Miami Project to Cure Paralysis, Department of Neurosurgery, University of Miami Miller School of Medicine, Miami, FL, USA.

Insights

Brain trauma causes oligodendrocyte (OL) death. The netrin-1/deleted in colorectal cancer (DCC) pathway regulates this loss, offering a potential therapeutic target for improving myelin repair and motor function after injury.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pathology

Background:

  • Traumatic brain injury (TBI) leads to axonal degeneration and demyelination.
  • Oligodendrocytes (OLs), responsible for myelin production, are highly vulnerable to injury-induced death signals.
  • Dependence receptors (DepRs) are a class of receptors that initiate pro-death signaling in the absence of their ligands, but their role in TBI is largely unknown.

Purpose of the Study:

  • To investigate the role of the deleted in colorectal cancer (DCC) dependence receptor in oligodendrocyte loss following brain injury.
  • To explore the therapeutic potential of the netrin-1/DCC pathway in mitigating TBI-induced OL death and promoting myelin repair.

Main Methods:

  • Examined the expression of DCC and its ligand netrin-1 in perilesional tissues after acute brain injury.
  • Administered netrin-1 to assess its effect on OL cell death.
  • Utilized DCCD1290N mutant mice with silenced pro-death activity to evaluate OL survival, myelin integrity, and motor function post-injury.

Main Results:

  • Netrin-1 administration effectively blocked oligodendrocyte cell death.
  • DCC expression was upregulated, while netrin-1 expression was downregulated in injured brain tissues.
  • Genetic silencing of DCC's pro-death activity in mutant mice resulted in increased OL survival, preserved myelin integrity, and improved motor function.

Conclusions:

  • The netrin-1/DCC pathway plays a critical role in regulating oligodendrocyte loss after traumatic brain injury.
  • Targeting this pathway presents a novel therapeutic strategy for enhancing recovery and functional outcomes in TBI patients.